Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
66.5M
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
4.62M
-
Shares change
-
+4.62M
-
Total reported value, excl. options
-
$9.56M
-
Value change
-
+$9.56M
-
Number of buys
-
21
-
Price
-
$2.06
Significant Holders of Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) as of Q2 2022
22 filings reported holding RGLS - Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share as of Q2 2022.
Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share (RGLS) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.62M shares
of 66.5M outstanding shares and own 6.95% of the company stock.
Largest 10 shareholders include FEDERATED HERMES, INC. (2.9M shares), DAFNA Capital Management LLC (556K shares), VANGUARD GROUP INC (373K shares), VICTORY CAPITAL MANAGEMENT INC (222K shares), Sarissa Capital Management LP (185K shares), Ikarian Capital, LLC (105K shares), GEODE CAPITAL MANAGEMENT, LLC (71.9K shares), STATE STREET CORP (41.7K shares), RENAISSANCE TECHNOLOGIES LLC (28.1K shares), and CITADEL ADVISORS LLC (23.7K shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.